Translate this page into:
Hyperprogression after nivolumab for the treatment of melanoma
Corresponding author: Dr. Alexandra Perea Polak, Department of Dermatology, Hospital Regional Universitario de Málaga, Plaza Hospital Civil, Málaga, Spain. a.pereapolak@hotmail.com
-
Received: ,
Accepted: ,
How to cite this article: Perea Polak A, Martínez García S, Godoy Díaz DJ. Hyperprogression after nivolumab for the treatment of melanoma. Indian J Dermatol Venereol Leprol 2023;89:616–7.
We report a 84-year-old man with stage IIIC melanoma: T3b, N0, M0 (American Joint Committee on Cancer, AJCC8) and BRAF +, who was treated with vemurafenib followed by nivolumab due to progressive cutaneous and subcutaneous disease [Figure 1]. The patient initially responded to our treatment, but after some months, he presented with disease hyperprogression infiltrating the entire thoracoabdominal wall [Figure 2] and finally succumbed to it.
- Presence of gynecomastia and multiple skin metastases of melanoma in the chest and abdomen
- Infiltration by melanoma of the entire thoracoabdominal wall
Checkpoint inhibitors are effective therapeutic options for melanoma. However, a subset of patients presents with hyperprogressive disease on continuous use of anti-programmed cell death-1 agents, similar to our case.
Declaration of patient consent
The patient’s consent is not required as the patient’s identity is not disclosed or compromised.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
